OncoMatch/Clinical Trials/NCT05981209
Elotuzumab, CC-92480, and Dexamethasone for the Treatment of Relapsed or Refractory Myeloma After CD38- and BCMA-Targeted Therapies
Is NCT05981209 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments including Elotuzumab and Mezigdomide for recurrent multiple myeloma.
Treatment: Dexamethasone · Elotuzumab · Mezigdomide — This phase Ib trial tests the safety, side effects, and best dose of CC-92480 in combination with elotuzumab and dexamethasone in treating patients with multiple myeloma that has come back after a period of improvement (relapsed) or that does not respond to treatment or has not responded to previous treatment (refractory). Multiple myeloma (MM) remains the second most common hematologic malignancy in the United States. A number of therapies have been approved for patients with MM, including CD38- and B-cell maturating antigen (BCMA)-targeted therapies (antibody and plasma cell treatments that help the body's immune system to kill cancer cells); however, patients will often relapse and become refractory to these therapies. Because of this, it is important to identify effective treatment options for patients progressing on anti-CD38 therapy and BCMA-directed therapies. Elotuzumab is a humanized IgG1 monoclonal antibody, which is a type of protein that can bind to other target cells to prevent them from working the way they should or cause them to act differently. Elotuzumab works by targeting a protein called SLAMF7, which is present on myeloma cells, and makes it easier for the immune system to target the cancer. CC-92480 works by binding to a protein called CRBN that triggers the breakdown of proteins: Ikaros and Aiolos, leading to cell death in multiple myeloma cells. Dexamethasone is a synthetic adrenocortical steroid, or steroid normally naturally made by the adrenal gland in the brain which has been produced in a laboratory, that helps to regulate the amount of different chemicals and water that are being processed by the kidneys. It is also used in patients with myeloma to help treat their disease. The combination of CC-92480 with elotuzumab and dexamethasone may be a safe and effective treatment when given to patients with relapsed or recurrent MM.
Check if I qualifyExtracted eligibility criteria
Cancer type
Multiple Myeloma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: immunomodulatory drug (lenalidomide)
including lenalidomide
Must have received: proteasome inhibitor
including ... proteasome inhibitor (PI)
Must have received: anti-CD38 directed antibody
including ... anti-CD38 directed antibody
Must have received: BCMA-targeted therapy
including ... BCMA-targeted therapy
Cannot have received: elotuzumab (elotuzumab)
Exception: Prior elotuzumab is permitted but patients with progressive disease (PD) as best response on elotuzumab are excluded; at least 6 months must have lapsed from prior elotuzumab exposure
Prior elotuzumab is permitted but patients with progressive disease (PD) as best response on elotuzumab are excluded; at least 6 months must have lapsed from prior elotuzumab exposure
Lab requirements
Blood counts
Hemoglobin >= 7g/dL; ANC >= 1000/uL; Platelets >= 70,000/uL (if plasma cell % > 30%, platelets >= 50,000/uL)
Kidney function
Calculated creatinine clearance of >= 45ml/min using MDRD formula
Liver function
Total bilirubin <= 1.5 x ULN; AST/ALT/alkaline phosphatase < 2.5 x ULN
Cardiac function
Left ventricular ejection fraction >= 30%; no uncontrolled arrhythmias; no NYHA class III-IV heart failure; QTcF <= 470 msec
Hemoglobin >= 7g/dL; ANC >= 1000/uL; Platelets >= 70,000/uL (if plasma cell % > 30%, platelets >= 50,000/uL); Total bilirubin <= 1.5 x ULN; AST/ALT/alkaline phosphatase < 2.5 x ULN; Calculated creatinine clearance of >= 45ml/min using MDRD formula; Left ventricular ejection fraction >= 30%; no uncontrolled arrhythmias; no NYHA class III-IV heart failure; QTcF <= 470 msec
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Ohio State University Comprehensive Cancer Center · Columbus, Ohio
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify